Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $20.2857.

Several research analysts have commented on the company. Rodman & Renshaw assumed coverage on Enanta Pharmaceuticals in a research report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Commodore Capital LP purchased a new position in Enanta Pharmaceuticals in the third quarter valued at about $9,576,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $6,660,000. Spruce Street Capital LP purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $6,145,000. Strs Ohio purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Enanta Pharmaceuticals by 333.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 2,758 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Trading Up 5.5%

Shares of ENTA opened at $12.07 on Wednesday. The firm has a market capitalization of $351.00 million, a P/E ratio of -4.66 and a beta of 0.97. The stock’s fifty day simple moving average is $13.39 and its 200 day simple moving average is $13.69. Enanta Pharmaceuticals has a twelve month low of $6.43 and a twelve month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.The company had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million. Sell-side analysts predict that Enanta Pharmaceuticals will post -1.79 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.